Abstract
Hypersensitivity reactions to β-lactam antibiotics are commonly reported. They can be classified as immediate or non-immediate according to the time interval between the last drug administration and their onset. Immediate reactions occur within one hour after the last drug administration and are manifested clinically by urticaria and/or angioedema, rhinitis, bronchospasm, and anaphylactic shock; they may be mediated by specific IgEantibodies. Non-immediate reactions occur more than one hour after the last drug administration. The most common manifestations are maculopapular exanthemas; specific T lymphocytes may be involved in this type of manifestation. In the diagnostic evaluation of hypersensitivity reactions to β -lactam antibiotics, the patient’s history is fundamental. The allergy examination is based on in vitro and in vivo tests selected on the basis of the clinical features and the type of reaction, immediate or non-immediate. Immediate reactions can be assessed in vitro by serum specific IgE assays and basophil activation tests and in vivo by immediate-reading skin tests and, in selected cases, drug provocation tests (DPTs). Non-immediate reactions can be evaluated mainly by delayed-reading skin tests, patch tests, and DPTs.
Keywords: Allergy, antibiotics, β-lactams, hypersensitivity, immediate, non-immediate, patch tests, skin tests.
Current Pharmaceutical Design
Title:Diagnosing β-Lactam Hypersensitivity
Volume: 22 Issue: 45
Author(s): Francesco Gaeta, Maria J. Torres, Rocco Luigi Valluzzi, Cristiano Caruso, Cristobalina Mayorga and Antonino Romano
Affiliation:
Keywords: Allergy, antibiotics, β-lactams, hypersensitivity, immediate, non-immediate, patch tests, skin tests.
Abstract: Hypersensitivity reactions to β-lactam antibiotics are commonly reported. They can be classified as immediate or non-immediate according to the time interval between the last drug administration and their onset. Immediate reactions occur within one hour after the last drug administration and are manifested clinically by urticaria and/or angioedema, rhinitis, bronchospasm, and anaphylactic shock; they may be mediated by specific IgEantibodies. Non-immediate reactions occur more than one hour after the last drug administration. The most common manifestations are maculopapular exanthemas; specific T lymphocytes may be involved in this type of manifestation. In the diagnostic evaluation of hypersensitivity reactions to β -lactam antibiotics, the patient’s history is fundamental. The allergy examination is based on in vitro and in vivo tests selected on the basis of the clinical features and the type of reaction, immediate or non-immediate. Immediate reactions can be assessed in vitro by serum specific IgE assays and basophil activation tests and in vivo by immediate-reading skin tests and, in selected cases, drug provocation tests (DPTs). Non-immediate reactions can be evaluated mainly by delayed-reading skin tests, patch tests, and DPTs.
Export Options
About this article
Cite this article as:
Gaeta Francesco, Torres J. Maria, Valluzzi Luigi Rocco, Caruso Cristiano, Mayorga Cristobalina and Romano Antonino, Diagnosing β-Lactam Hypersensitivity, Current Pharmaceutical Design 2016; 22 (45) . https://dx.doi.org/10.2174/1381612822666161004124535
DOI https://dx.doi.org/10.2174/1381612822666161004124535 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot Topic: Advances in Diagnosing Drug Hypersensitivity Reactions (Executive Editors: A. Romano and M. Ventura)]
Current Pharmaceutical Design The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Giardiasis in the Post Genomic Era: Treatment, Drug Resistance and Novel Therapeutic Perspectives
Infectious Disorders - Drug Targets Prevalence of Intestinal Parasites among Patients with Chronic Urticaria in Northern Iran
Infectious Disorders - Drug Targets New Applications for Sublingual Immunotherapy in Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Topical Imiquimod: Mechanism of Action and Clinical Applications
Mini-Reviews in Medicinal Chemistry Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Renin-Angiotensin System in Diabetes
Protein & Peptide Letters Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Hypertension in Hemodialysis Patients
Current Hypertension Reviews Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry PARADIGM - HF: The Rise of the Arnis
Reviews on Recent Clinical Trials Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Contact Allergy to Topical Corticosteroids: Update and Review on Cross- Sensitization
Recent Patents on Inflammation & Allergy Drug Discovery The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design C1-Inhibitor: Structure, Functional Diversity and Therapeutic Development
Current Medicinal Chemistry Healthcare Management During A Pandemic: The Other Side of the Coin for the Treatment of COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets